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Abstract: The pathological description of the stage of a tumor is an important clinical designation and is considered, like many other forms of
biomedical data, an ordinal outcome. Currently, statistical methods for predicting an ordinal outcome using clinical, demographic, and high-dimensional
correlated features are lacking. In this paper, we propose a method that fits an ordinal response model to predict an ordinal outcome for high-dimensional
covariate spaces. Our method penalizes some covariates (high-throughput genomic features) without penalizing others (such as demographic and/or clinical
covariates). We demonstrate the application of our method to predict the stage of breast cancer. In our model, breast cancer subtype is a nonpenalized predictor, and CpG site methylation values from the Illumina Human Methylation 450K assay are penalized predictors. The method has been made available
in the ordinalgmifs package in the R programming environment.
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Introduction

Ordinal outcomes, or any outcome with inherent ordering,
occur frequently in biomedical data. Examples of these types
of ordered responses include severity of depression, grading of
adverse events, the Knodell score for liver biopsies,1 or stage
of cancer. Stage of cancer is a pathological description of a
tumor, and for breast cancer it considers the following: size
of the tumor, number of cells in the tumor, location of tumor
with respect to the chest wall and skin, the amount of cancer
in mammary, axillary, and sentinal lymph nodes, the number
of lymph nodes involved, and the spread of cancer to other
organs.2 Stage of cancer typically determines the course of
therapy and is most often ascertained through a biopsy of the
cancerous tissue. When modeling stage of cancer, it may be of
interest to predict which response level a patient may exhibit,
given some set of explanatory variables. Ordinal regression
may be used to model the probability of exhibiting a specific ordinal response, given some set of relevant covariates.
However, ordinal regression methods require either that the
sample size exceeds the number of features or that all covariate parameters be penalized. It is of interest here to develop
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a method that allows the model to penalize some covariates
without penalizing others (such as demographic covariates).
In our research, we are interested in using highdimensional methylation data from the Illumina Human
Methylation 450K technology, in conjunction with other factors, to predict stage of cancer in a sample of women with
breast cancer. Methylation is an epigenetic event that alters
gene expression without altering the DNA sequence itself.
It is the process by which a cytosine molecule on the DNA
strand becomes a 5-methylcytosine through the addition of
a methyl group, or a 5-hydroxymethylcytosine through the
addition of a methyl group followed by a hydroxy group. Profound methylation changes are known to occur in the context
of cancer; well-documented changes include the hypermethylation of tumor-suppressor genes3 and the hypomethylation of proto-oncogenes.4 Specific patterns of methylation
exhibited in tumors are thought to not only detect cancer5 but
also predict tumor behavior6 and illuminate differences and
similarities across and within tumor types. 3 Jones and Laird
stated that perhaps methylation patterns in cells could serve as
“a rough blueprint for the expression profile of that cell” and
Cancer Informatics 2015:14(S2)
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Methods

Data. In this paper, we worked with one dataset from
a breast cancer study conducted at Virginia Commonwealth
University. This research was approved by the Institutional
Review Board at Virginia Commonwealth University (VCU
IRB #HM 13194) and complied with the principles of the
Declaration of Helsinki. Our dataset included 73 women with
breast cancer and included baseline clinical and demographic
covariates such as estrogen receptor (ER), progesterone receptor
(PR), and human epidermal growth factor receptor 2 (HER2)
status, age, race (white or African-American), prior breast cancer surgery (lumpectomy, segmental, or simple surgery prior
to study enrollment), and smoking status (currently smoking,
yes or no). ER, PR, and HER2 status were collapsed into a
single, categorical measure of breast cancer subtype,9 defined
in Table 1.
Peripheral blood samples were collected at study entry,
and DNA was subsequently extracted from these samples
using standard methods, bisulphite converted (Zymo Research
EZ Methylation Kit), and hybridized to Illumina’s Human
Methylation 450K array according to the manufacturer’s protocol. To assess assay reliability, some samples were hybridized
multiple times, resulting in a total of 82 methylation profiles.
The scanned arrays were processed using the minfi10 Bioconductor package in the R programming environment to
obtain the β-values for each probe, where βig represents the

proportion methylated for the ith sample and the gth CpG
site, defined here as

	  

β=

M
M + U + offset

where M is the methylated signal for a given CpG site, U is
the unmethylated signal for a given CpG site, and offset is
100, to avoid division by small numbers.11
Some preprocessing of the methylation data was necessary prior to statistical analysis. Our first preprocessing step
was to look at the distribution of β-values by the GC content.
This is important because previous research has established
that methylation may not be accurately measured in regions
of high GC content.12 Illumina’s design for the 450K array
includes two separate assays, Type I and Type II, for estimating methylation at a given locus. GC content was calculated as
the proportion of the probe sequence comprised of C’s and G’s
and reported separately for Type I and Type II design types.
We then examined the boxplots of average β-values (across
all samples) by the GC content for each of the assay types
separately (Figs. 1 and 2). The resulting boxplots were used to
determine a GC proportion cutoff value beyond which methylation seems to no longer be reliably measured. The choice of
such a cutoff is clearly subjective, but it is important to remove
the CpG sites beyond the cutoff because inclusion of unreliable probes may distort the analysis. We also removed CpG
sites within which there were known single nucleotide polymorphisms (SNPs) according to the Illumina-provided annotation files.11
The Type I design includes two bead types for each CpG
site: one that detects methylated CpG sites, and the other
GC Content, Type I
1.0

0.8

0.6

β

envisioned that future development of science and technology
might produce a useful methylation analysis to generate a
“DNA methylation fingerprint for a tumor biopsy.” 7 Studies
of methylation patterns in peripheral blood specimens from
people diagnosed with cancer have also shown alterations. Of
particular relevance, DNA methylation analysis from peripheral blood samples recently identified an association between
methylation of the HYAL2 gene and breast cancer,8 suggesting that methylation patterns in blood might be useful as a
screening tool for evaluating tumors in other tissues. Because
epigenetic changes, such as methylation, are reversible, identification of specific methylation changes occurring in specific
cancers may lead to targeted therapies to return normal function to the cells.7 Given this evidence, we hypothesized that
differential methylation may be predictive of stage of cancer in
women with breast cancer.

0.4

Table 1. Criteria for breast cancer subtype classification.
Subtype

Definition

Luminal A

ER+ and/or PR+, HER2−

Luminal B

ER+ and/or PR+, HER2+

Triple negative

ER−, PR−, HER2−

HER2 Type

ER−, PR−, HER2+

Notes: Breast cancer subtype classification typically considers proportion of
tumor cells positive for the Ki67 protein. This measurement was not collected
in our study and therefore could not be used for classification.

202

Cancer Informatics 2015:14(S2)

0.2

0.0
18

24

30

36

42

48

54

60

66

Percentage
Figure 1. Boxplot of mean β-values by percent GC content across all
samples, for type I probes.
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Figure 2. Boxplot of mean β-values by percent GC content across all
samples, for type II probes.

that detects unmethylated CpG sites. The Type II design
includes a single bead with a two-color readout; a different
color is used to indicate whether the CpG site is methylated
or unmethylated. In 2011, Dedeurwaerder et al examined
the distribution of β-values produced by Type I and Type II
bead types used in the 450K technology.13 They noted that
the distribution of β-values from both bead types, across the
whole array, exhibited two distinct peaks, one close to 0 for
the unmethylated CpGs and one close to 1 for the methylated CpGs. These peaks, however, when modeled separately
by bead type, did not align exactly; the peaks for the β-values
from the Type II beads were shifted inwards when compared
to the Type I beads. This shift is attributed to the difference
in chemistry between the beads and is acknowledged by Illumina in a Technical Note for the 450K technology on their
Web site.14 To correct this issue, we implemented the peak
correction method by Dedeurwaurder et al on our β-values as
a preprocessing step. This method adjusts the Type II peaks
so that they align to the locations of the Type I peaks. The
peak correction method uses the M-values and the logit of the
β-values

	  


βig
M ig = log 
 1− β
ig


(

)


 .



Prior to the logit transformation and peak correction, we
modified the β-values slightly by adding or subtracting 0.001
to any β-value exactly equal to 0 or 1, respectively, in order to
prevent errors during the logit transformation.
Finally, there were five patients having n1 = 4, n2 = 4,
n 3 = 2, n4 = 2, and n5 = 2 hybridized samples each. For

each of these patients, we averaged the final peak-corrected
M-values across the replicate samples and used this single,
mean signal for each of these five patients in our analysis.
All data analyses were conducted in R (version 3.1.0) utilizing the minfi10 (version 1.10.2), limma15 (version 3.16.8),
VGAM (version 0.9–4),16 and ordinalgmifs17 (version 1.0.2)
packages. In our analysis, we used the 450K annotation file
version 1.2.18
Analysis. In genomic research, traditional modeling
methods are often inappropriate. Traditional ordinal regression methods, for example, require that the number of predictors (p) be smaller than the sample size (n) and that the
predictors be independent. After filtering, our breast cancer study included 353,331 CpG sites and only 73 patients;
such a situation, where p .. n, is typical when analyzing
high-throughput genomic data. Furthermore, we know that
methylation levels of CpG sites in close proximity to one
another are highly correlated. To handle these challenges,
we implemented penalized regression methods. Penalized
regression introduces bias into the model in exchange for
reducing variability.19 The resulting model is sparse, which is
an attractive feature when dealing with an overly large predictor space and we are interested in producing a parsimonious model.
There are a variety of algorithms available for finding a
penalized solution. One such algorithm is the Incremental Forward Stagewise (IFS) method, which provides the monotone
Least Absolute Shrinkage and Selection Operator (LASSO)
solution in a linear regression setting.20 Hastie et al modified
and extended the IFS procedure, creating the generalized
monotone incremental forward stagewise (GMIFS) method,
which provides a penalized solution in a logistic regression
setting.20 Archer et al further extended the GMIFS method
to provide the penalized solution in an ordinal regression setting.21 In our work, we extended the GMIFS algorithm to
allow a subset of covariates to be included in the model without penalization.
This so-called no-penalty subset, the subset of demographic variables not penalized, is included in the final model,
and the fitting algorithm is not allowed to shrink any of these
coefficients to 0. This no-penalty subset option is important
in many scientific investigations where some biologically
relevant demographic information should be retained in the
model, regardless of statistical significance ascribed to the
given covariates. For our breast cancer dataset, we fit univariate ordinal response models predicting stage for each of the
following: age, race, body mass index (BMI), smoking status,
prior surgery related to the management of breast cancer, and
subtype, to see which of these will be important for inclusion in the full ordinal model. We conducted a likelihood ratio
test (LRT) to obtain the P-values for each of these univariate
models. We used a P-value cutoff of 0.05 to determine which
demographic covariates were important for inclusion in the
no-penalty subset.
Cancer Informatics 2015:14(S2)
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Given the large number of CpG sites in the 450K
array, we first filtered the M-values by significance in order
to reduce the number of penalized coefficients considered by
the model. We fit a model with only the demographic covariates found to be important from the previous LRTs and each
of the CpG sites individually. We then conducted a series of
LRTs between the demographic-only model and each of the
CpG site models. Using a liberal P-value threshold of 0.25,
we included in the penalized model only those CpG sites with
a P-value ,0.25. Additionally, we removed CpG sites that
were universally unmethylated (β , 0.1) across all samples
and those that were universally methylated (β . 0.9) in all
samples. Removing these CpG sites constituted no loss of
information since all the samples were either fully unmethylated or fully methylated.
The primary outcome measure of interest, as mentioned,
was stage of cancer. Stage of cancer is measured as 0–IV and
may be further subdivided into 0, IA-B; IIA-B; IIIA–C; and
IV. The patients in our study, which focused on ascertaining
participants with early stage breast cancer, were classified as
stage I (n = 21), IIA (n = 29), IIB (n = 15), or IIIA (n = 8). We
constructed a response matrix y which was an n × k matrix
representing class membership. For i = 1,…, n, subjects may
take one of j = 1,…, k stages (ordinal levels), and the elements
of the matrix are
1, if observation i is in stage j
yij = 0, otherwise.


	  

We also constructed a matrix of nonpenalized predictors z
and a matrix of penalized predictors x. Using a cumulative
logit model to model the k – 1 logits of ordinal categories
at or below a given level, the probability of interest may be
expressed as follows:

Therefore, the likelihood is given by

	  
and the log-likelihood is given by

	  
which can be more formally expressed as

The specific steps of the modified GMIFS algorithm
to obtain this solution are implemented in the ordinalgmifs
package in R.17 We outline the steps for the cumulative logit
form of the model here.
Beginning at step s = 0,
Augment the x covariate space by appending the negative
of the covariate space so that x becomes [x: –x].*
*We augment the covariate space in this way so that we may
avoid calculation of the second derivative to determine the direction
of the update.20
2. Set all of the β terms to 0 so that
(The β vector is of length 2p)
y
3. Initialize the α terms as α j = logit ∑ ni = 1 ∑ kj = 1 nij .
1.

4.
5.

6.

	  
where αj ’s represent the intercepts and β, and θ represent the
coefficients for the penalized and nonpenalized predictors,
respectively. In this way, we modeled the conditional probability that, given values of the demographic and methylation
covariates, the cancer classification for a patient would fall at
or below a certain stage. The conditional probability that the
cancer classification would fall exactly at a certain stage may
be written as

(
	 
204

(

)

)
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7.

(

)

Holding the β terms fixed, update α and θ by maximum
likelihood.
δ
Holding α and θ fixed, find m = argmin −
log L .
δβ p
p
Update βms+1 to be β ms+ 1 + ε , where ε is some small value.
We used ε = 0.01.
Repeat steps 4–6 until log L(s+1) − log L(s) , τ, where τ is
some small value. We used τ = 0.00001.

( )

Once the algorithm converges, the parameter estimates
achieved constitute the “converged model.” For each step of
the algorithm, we calculated the log likelihood, Akaike Information Criterion (AIC), and the Bayesian Information Criterion (BIC) for the model at that iteration of the algorithm.
AIC and BIC are measures of the relative quality of a statistical model. We then extracted the parameter estimates at the
step that minimized the AIC.
The penalized covariates are given by x, with β denoting the corresponding parameter estimates. As indicated in
step 2 of the algorithm, at the first step all the β’s are set to
zero. For each consecutive step of the algorithm, only one β

Penalized ordinal method for predicting stage of cancer

is updated by a very small incremental amount. As indicated
in steps 5 and 6 of the algorithm, the β that is updated is that
which corresponds to the predictor having the largest negative
derivative of the log likelihood. After a β has been updated,
the thresholds and unpenalized predictors are estimated by
maximum likelihood keeping the β fixed (see step 4 of the
algorithm). For this reason, some predictors are penalized (x)
while others are not penalized (z). The penalized β estimates
are found when the log likelihood is minimized with respect
to the following constraints:

β g+, β g− ≥

G

0 and ∑

g=1

(

β g+ +

β g−

)≤ s

The value of s is not specified by the user. Rather, each of the
s values corresponds to a specific solution 20 so that both the
AIC-selected and the converged model will have an associated s value. Note that this method is an incremental forward
stagewise method, which differs from preselecting a tuning
parameter, or set of tuning parameters, against which the
model is fit, then subsequently selecting the best fitting model
by some model-fitting criterion.
For our selected model, we were interested in how the
blood methylation values predicted the stage of the actual
tumor. For the nonzero coefficient estimates, we investigated
whether any of the differentially methylated loci had been previously associated with breast cancer or other types of cancer.
Simulation study. We also conducted a simulation study
to further test the performance of the method. Currently, there
exists no comparative method that fits a penalized cumulative
logit model, so we have no method against which to test the
GMIFS cumulative logit model performance. For our simulation study, we used a sample size of 80 subjects, where 100
predictor variables were generated from a uniform distribution
on the [–1, 1] interval. Thereafter, the latent response, yi* for
i = 1,…, 80, was generated by using the first four predictors
(X1,…, X4) as covariates truly associated with the response
where the coefficients were (0.5, –0.5, 0.5, –0.5) and adding
a Gaussian error term with mean 0 and standard deviation of
0.15. The observed response was generated by referencing the
probabilities of the generated latent response using a standard
normal distribution, where the observed class was taken to be

( )

	  

1 if P y * ≤ 0.25
i

if
2
0
25
.
< P yi* ≤ 0.50

yi = 
.
3 if 0.50 < P yi* ≤ 0.75

4 if P yi* > 0.75


( )

( )
( )

(1)

Thereafter, a cumulative logit GMIFS model was fit using
X1 as an unpenalized predictor and X 2, X3, X4 as penalized
predictors and the AIC selected model was examined. This
entire process was repeated 50 times. Characteristics of the
fitted models examined included the number of times the

coefficients for X 2, X3, and X4 were nonzero (true positive
rate); the number of times the coefficients for X5,…, X100 were
nonzero (false positive rate); and the misclassification rate.
Our simulation study indicated that the method performed well. The true positive rate was 100%, as all models
returned nonzero coefficient estimates for X 2, X3, and X4. The
median false positive rate was 5.2% (range 0–33%). The median
misclassification rate was 13.75% (range 1.25–30.00%).

Results

Table 2 provides an overview of the distribution of the continuous and binary demographic covariates by stage of cancer.
Table 3 provides the distribution of the multi-level categorical
covariate.
The original, unfiltered data had 485,512 CpG sites.
The boxplots of GC content by CpG site (Figs. 1 and 2)
indicate that methylation may not be accurately measured
beyond 42% for Type I probes or beyond 40% for Type II
probes. After examining these boxplots, we chose the more
conservative of the two values and excluded CpG sites with
greater than 40% GC content from further analysis. This GC
content filtering criteria removed 52,077 CpG sites, leaving
433,435 CpG sites. Next we removed the 80,104 CpG sites
that included SNPs, leaving 353,331 CpG sites. There were
1,742 β-values exactly equal to 0, while none were exactly
equal to 1. We imputed those equal to 0 to be 0.001 before
applying the logit transform. After this, we applied the peak
correction method to align the Type II peaks to the locations
of the Type I peaks. An LRT was conducted for each of the
demographic covariates comparing the intercepts-only model
to each of the univariate models when fitting cumulative logit
models to predict stage of cancer. The results of these tests are
given in Table 4.
Table 2. Demographic characteristics by stage of cancer. The
medians are reported for continuous variables (age and BMI) and
the frequencies are reported for categorical variables (race, smoking
status, and prior surgery).
Stage

I
n = 21

IIA
n = 29

IIB
n = 15

IIIA
n=8

Total
n = 73

Age (median)
BMI (median)

55
29.58

48
25.79

56
31.01

49
29.25

53
28.34

Race (Black)
Currently smoking (Y)
Prior surgery (Y)

5/21
3/21
21/21

10/29
5/29
26/29

6/15
6/15
12/15

0/8
1/8
7/8

21/73
15/73
66/73

Table 3. Frequencies of breast cancer subtype by stage of cancer.
Stage

I
n = 21

IIA
n = 29

IIB
n = 15

IIIA
n=8

Total
n = 73

Luminal A

7

16

7

7

37

Luminal B

2

3

3

0

8

Triple negative

11

7

2

1

21

HER2 type

1

3

3

0

7
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Table 4. LRT and resulting P-values from univariate cumulative logit models predicting stage of cancer.

Deviance
χ 12 statistic

Intercepts only

Age

BMI

Race

Currently smoking

Prior surgery

Subtype

188.72

187.57
1.15

188.70
0.02

188.69
0.03

187.56
1.16

185.70
3.02

179.91
8.81*

0.2834

0.8787

0.8611

0.2821

0.0824

0.0319

P-Value
Note:

* χ 32

statistic.

In the interest of developing a parsimonious model,
we used a P-value cutoff of 0.05. At this significance level,
it was clear that only subtype (eg, Luminal A; Luminal B;
HER2+; triple negative) was significantly related to stage

of breast cancer in this univariate sense. A similar LRT was
conducted for each of the 353,331 CpG sites using the filtered,
peak-corrected β-values. The model for the LRTs included
only the demographic variable for cancer subtype. After

Table 5. AIC-selected CpG sites listed with their chromosome, position, and associated UCSC ref genes, where appropriate.
CpG site

Chromosome

Location (start)

Location (end)

UCSC Ref Gene

cg01393985

6

89927651

89927700

GABRR1

cg02873991

12

25151263

25151312

C12orf77

cg02990147

X

24329623

24329672

FAM48B2

cg03478356

9

45726913

45726962

FAM27A

cg03604519

X

70150242

70150291

SLC7A3

cg03642328

11

69624925

69624974

FGF3

cg04315214

1

2043799

2043848

PRKCZ

cg05898699

18

15197299

15197348

cg06159404

10

43846376

43846425

cg06618740

1

1100126

1100175

cg07068358

16

25879737

25879786

HS3ST4

cg07078747

12

34177660

34177709

ALG10

cg07850592

1

231299396

231299445

TRIM67

cg08314875

Y

15015601

15015650

DDX3Y

cg08407901

21

43989901

43989950

SLC37A1

cg08615372

19

18699234

18699283

C19orf60

cg08833952

22

22469409

22469458

cg09667394

1

78011748

78011797

cg10139947

2

105274650

105274699

cg10467557

13

21893614

21893663

cg12386614

1

33608005

33608054

cg12440927

7

157791673

157791722

cg13033971

13

46291925

46291974

cg14468658

5

140723461

140723510

cg14884760

22

50164389

50164438

cg16807687

10

85973970

85974019

cg19009644

3

10553211

10553260

cg19149522

7

6616375

6616424

ZDHHC4

cg19893664

14

105619634

105619683

JAG2

cg20418394

10

72254335

72254384

KIAA1274

cg21156276

9

4491869

4491918

SLC1A1

cg24493834

6

129250963

129251012

LAMA2

cg25099892

13

113313857

113313906

C13orf35

cg26479305

12

52470979

52471028

C12orf44

cg27161197

12

47224649

47224698
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Beta−values for methylation of cg19149552
0.9

β

0.8

Table 6. Cross-tabulation of the observed (rows) versus predicted
(columns) class for the AIC and the fully converged models.
AIC

I

IIA

IIB

IIIA

Converged

I

IIA

IIB

IIIA

I

20

1

0

0

I

21

0

0

0

IIA

0

29

0

0

IIA

0

29

0

0

IIB

0

4

11

0

IIB

0

0

15

0

IIIA

0

0

6

2

IIIA

0

0

0

8

0.7

0.6

0.5
I

IIA

IIB

IIIA

Stage of cancer
Figure 3. Boxplot of β-values for CpG site cg19149522 (ZDHHC4), for all
subjects, by stage of cancer.

excluding CpG sites with P-values greater than 0.25, 103,001
CpG sites remained. Finally, after excluding CpG sites for
which the β-value was ,0.1 or .0.9 in all samples, 27,110
CpG sites remained. The ordinal cumulative logit GMIFS
model was fit to the subtype covariate as a nonpenalized predictor and to the M-values for the 27,110 CpG sites as penalized predictors. The model attaining minimum AIC included
35 nonzero CpG sites (Table 5), while the fully converged
model estimated 107 nonzero CpG sites. Subsequently, we
ran the model again, this time filtering to exclude CpG sites
Beta−values for methylation of cg16807687

0.85
0.80

β

0.75
0.70
0.65
0.60

I

IIA

IIB

IIIA

Stage of cancer
Figure 4. Boxplot of β -values for CpG site cgl6807687 (PCDH21), for all
subjects, by stage of cancer.

with P-values greater than 0.05. Fitting the same GMIFS
model to this smaller set of CpG sites resulted in exactly the
same parameter estimates and class predictions as the previous
model, which used a P-value cutoff of 0.25.
Boxplots (Figs. 3 and 4) are shown for the two CpG sites
from Table 5 with the largest absolute coefficient. The plots
display the distribution of β-values for all subjects according
to stage of cancer. The β-values for cg19149522 (ZDHHC4)
seem to be monotonically decreasing, while the β-values for
cg16807687 (PCDH21) seem to be monotonically increasing.
The fully converged model predicted the stage without
error, while the minimum AIC model had an error rate of
15.1%. Table 6 shows the cross-tabulation of observed versus
predicted class. The fully converged model was without error;
however, it included 107 nonzero parameter estimates indicating that it is likely overfit. The AIC model was less accurate
for prediction, particularly for patients with stage IIIA cancer.
This is likely due to the fact that our patient sample is unbalanced across the stages and is biased toward stages I–IIB.

Discussion

In this paper, we presented an ordinal response model for
high-dimensional covariate spaces that allows the inclusion
of nonpenalized covariates, penalized covariates, or both.
This method can be applied to any cumulative link, forward
continuation ratio, backward continuation ratio, adjacent
category, or stereotype logit model using the ordinalgmifs R
package.17 While the fully converged model had 100% accuracy in predicting stage of cancer, there were several misclassifications for the AIC-selected model. This may be partially
attributed to the imbalance and small class size, particularly
for stage IIIA. However, several of the CpG sites included
in the models were located within genes that have previously
been associated with breast cancer. AK5, PTPRN2, LAMA2,
FGF3, SLC37A1, and SLC1A1 have all been previously
associated with breast cancer.22–28 SLC7A3, PRKCZ, JAG2,
GABRR1, DDX3Y, and PCDHGA3 have been previously
associated with other types of cancer.29–34 Our results, which
agree with previously published results, indicate that methylation patterns of the tumor itself may impact the methylation patterns present in peripheral blood. Development of a
model that can accurately predict stage of cancer from DNA
methylation or other genomic profiles from peripheral blood
samples and demographic information may have important
Cancer Informatics 2015:14(S2)
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healthcare implications. We hope that our work here will help
future development of less invasive, less expensive methods for
determining the stage of cancer.
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